Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Seres Therapeutics (MCRB) Return on Capital Employed: 2016-2025

Historic Return on Capital Employed for Seres Therapeutics (MCRB) over the last 10 years, with Sep 2025 value amounting to -0.85%.

  • Seres Therapeutics' Return on Capital Employed fell 15.00% to -0.85% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.85%, marking a year-over-year decrease of 15.00%. This contributed to the annual value of -0.58% for FY2024, which is 18.00% up from last year.
  • According to the latest figures from Q3 2025, Seres Therapeutics' Return on Capital Employed is -0.85%, which was up 4.65% from -0.89% recorded in Q2 2025.
  • In the past 5 years, Seres Therapeutics' Return on Capital Employed ranged from a high of -0.14% in Q3 2021 and a low of -1.08% during Q3 2022.
  • Moreover, its 3-year median value for Return on Capital Employed was -0.70% (2024), whereas its average is -0.64%.
  • Per our database at Business Quant, Seres Therapeutics' Return on Capital Employed tumbled by 94bps in 2022 and then surged by 86bps in 2023.
  • Quarterly analysis of 5 years shows Seres Therapeutics' Return on Capital Employed stood at -0.22% in 2021, then crashed by 52bps to -0.74% in 2022, then skyrocketed by 35bps to -0.39% in 2023, then slumped by 64bps to -1.03% in 2024, then decreased by 15bps to -0.85% in 2025.
  • Its Return on Capital Employed was -0.85% in Q3 2025, compared to -0.89% in Q2 2025 and -0.95% in Q1 2025.